No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Which Subsectors to Own and Which to Avoid – Wolfe Research
Noble Financial Maintains Traws Pharma(TRAW.US) With Buy Rating, Cuts Target Price to $6
Noble Financial Sticks to Their Buy Rating for Traws Pharma (TRAW)
Express News | Traws Pharma - on Nov 20, Receives Nasdaq Non-Compliance Notice as Co Fails to Meet Nasdaq Listing Rule 5550(B)(1)
Traws Pharma Faces Uncertain Future Amid Complex Onconova Merger
Traws Pharma Reports Promising Antiviral Drug Progress
Unlock the Full List